Zevenbergen Capital Investments LLC Purchases New Position in TransMedics Group, Inc. $TMDX

Key Points

• Zevenbergen Capital Investments LLC has purchased a new stake in TransMedics Group, acquiring 121,528 shares valued at approximately $16.3 million, representing about 0.36% of the company.
• Recent analyst ratings have varied, with Canaccord Genuity lifting their target price to $142.00 and maintaining a "buy" rating, while Wall Street Zen downgraded the stock from "buy" to "hold."
• TransMedics Group reported earnings of $0.92 per share for the last quarter, significantly surpassing analysts' expectations of $0.48, with a revenue increase of 37.7% year-over-year.

Zevenbergen Capital Investments LLC purchased a new stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 121,528 shares of the company's stock, valued at approximately $16,286,000. Zevenbergen Capital Investments LLC owned approximately 0.36% of TransMedics Group as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. NBC Securities Inc. bought a new position in shares of TransMedics Group during the 1st quarter worth approximately $25,000. Smartleaf Asset Management LLC lifted its position in shares of TransMedics Group by 44.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock worth $30,000 after buying an additional 135 shares in the last quarter. Quarry LP lifted its position in shares of TransMedics Group by 88.5% during the 1st quarter. Quarry LP now owns 592 shares of the company's stock worth $40,000 after buying an additional 278 shares in the last quarter. Hager Investment Management Services LLC lifted its position in shares of TransMedics Group by 38.3% during the 1st quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock worth $50,000 after buying an additional 205 shares in the last quarter. Finally, CWM LLC lifted its position in shares of TransMedics Group by 20.1% during the 1st quarter. CWM LLC now owns 925 shares of the company's stock worth $62,000 after buying an additional 155 shares in the last quarter. Institutional investors own 99.67% of the company's stock.

Analysts Set New Price Targets

TMDX has been the topic of several recent analyst reports. Canaccord Genuity Group lifted their target price on shares of TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a research report on Tuesday, July 15th. Wall Street Zen cut shares of TransMedics Group from a "buy" rating to a "hold" rating in a research report on Saturday, August 30th. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research report on Monday, August 25th. Stifel Nicolaus started coverage on shares of TransMedics Group in a report on Thursday, September 4th. They issued a "hold" rating and a $115.00 price target on the stock. Finally, Oppenheimer upped their price objective on TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research note on Tuesday, June 17th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $122.11.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $114.57 on Friday. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.86 and a quick ratio of 9.17. The business has a fifty day simple moving average of $116.15 and a two-hundred day simple moving average of $105.52. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $169.29. The company has a market capitalization of $3.91 billion, a P/E ratio of 59.36 and a beta of 2.18.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The business had revenue of $157.37 million during the quarter, compared to analyst estimates of $146.64 million. During the same period in the previous year, the business earned $0.35 EPS. TransMedics Group's revenue was up 37.7% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. On average, analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.